A “repurposed” drug that could prevent breast cancer as well as treat it will be offered to almost 300,000 women, NHS officials have revealed.
Anastrozole has been used to treat hormone-sensitive breast cancer.
But trials have shown it can also stop the disease from occurring in the first place. It’s predicted cases could be cut by by 49% over 11 years.
The drug will be offered to 289,000 post-menopausal women who are considered to have at least a moderate risk of breast cancer in England.
“This is the first drug to be repurposed though a world-leading new programme to help us realise the full potential of existing medicines in new uses to save and improve more lives,” NHS chief executive Amanda Pritchard said.
Anastrozole was first recommended as a preventive option by the National Institute for Health and Care Excellence (Nice) in 2017, but, with the drug unlicensed in this use, uptake remained low.
Now scientists have found the protective effect lasts for years after a woman has stopped taking the drug – and has been licensed by the Medicines and Healthcare products Regulatory Agency .
Lesley-Ann Woodhams, who has a family history of the condition, completed the full five-year course of anastrozole in January 2023 and described it as a “gift”.
Lesley-Ann Woodhams has a history of breast cancer in her family
“I’d watched my mum battle breast cancer and my risk was very high,” she said.
“I could live a life without constantly worrying or giving a thought to what could be if I’d developed breast cancer.
“It really was a gift, it gave my family and myself peace of mind and more importantly, a continued future to look forward to.”
How does it work?
The treatment is taken as a 1mg tablet, once a day for five years and works by cutting down the amount of oestrogen the body makes by blocking an enzyme called aromatase.
The most common side effects of the medicine are hot flushes, feeling weak, pain or stiffness in the joints, arthritis, skin rash, nausea, headache, osteoporosis, and depression.
Breast cancer is the most common cancer in England, with around 47,000 women in England diagnosed each year.
Baroness Delyth Morgan, chief executive at the charity Breast Cancer Now, said the move is a “major step forward” that will enable more women to reduce their chance of developing the disease.
Read more from Sky News:
Most people can’t identify lesser-known symptoms of breast cancer
Surgeons carry out caesarean and ovaries removal at same time to cut cancer risk
Cervical cancer treatment breakthrough could cut deaths by 35%
Health Minister Will Quince said: “We’ve already seen the positive effect anastrozole can have in treating the disease when it has been detected in post-menopausal women and now we can use it to stop it developing at all in some women.”
The moves adds to the NHS’s armoury of preventative breast cancer medication, with tamoxifen and raloxifene already licensed to prevent breast cancer.